公开(公告)号：US11884672B2

公开(公告)日：2024-01-30

申请号：US15931256

申请日：2020-05-13

申请人： Vertex Pharmaceuticals Incorporated

发明人： Upul Keerthi Bandarage ,  Cavan McKeon Bligh ,  Diane Boucher ,  Michael John Boyd ,  Michael Aaron Brodney ,  Michael Philip Clark ,  Veronique Damagnez ,  Lev Tyler Dewey Fanning ,  Robert Francis Fimognari ,  Gabrielle Simone Fleming ,  Kevin James Gagnon ,  Pedro Manuel Garcia Barrantes ,  Robert Daniel Giacometti ,  Simon Giroux ,  Ronald Lee Grey, Jr. ,  Samantha Guido ,  Amy Beth Hall ,  Sarah Carol Hood ,  Dennis James Hurley ,  Mac Arthur Johnson, Jr. ,  Peter Jones ,  Sarathy Kesavan ,  Mei-Hsiu Lai ,  Siying Liu ,  Adam Looker ,  Brad Maxwell ,  John Patrick Maxwell ,  Ales Medek ,  Philippe Marcel Nuhant ,  Kirk Alan Overhoff ,  Setu Roday ,  Stefanie Roeper ,  Steven M. Ronkin ,  Rupa Sawant ,  Yi Shi ,  Muna Shrestha ,  Marisa Sposato ,  Kathy Stavropoulos ,  Rebecca Jane Swett ,  Timothy Lewis Tapley ,  Qing Tang ,  Stephen Thomson ,  Jinwang Xu ,  Mariam Zaky ,  Kevin Michael Cottrell

IPC分类号： C07D487/04 ,  A61K9/16 ,  A61K31/4162 ,  C07D491/18 ,  C07D513/04 ,  C07D519/00 ,  C07F9/6561 ,  C07H15/26

CPC分类号： C07D487/04 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/4162 ,  C07D491/18 ,  C07D513/04 ,  C07D519/00 ,  C07F9/6561 ,  C07H15/26 ,  C07B2200/13

摘要： The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I):




tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

公开(公告)号：US11980633B2

公开(公告)日：2024-05-14

申请号：US17444033

申请日：2021-07-29

申请人： Vertex Pharmaceuticals Incorporated

发明人： Diane Boucher ,  Shawn M. Hillier ,  Wanjung Tsai ,  Brian Hare ,  William Markland ,  David A. Newsome ,  Marina S. Penney

IPC分类号： A61K31/704 ,  A61K9/127 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D471/04

CPC分类号： A61K31/704 ,  A61K9/1271 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D471/04

摘要： Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.

公开(公告)号：US20220088043A1

公开(公告)日：2022-03-24

申请号：US17444033

申请日：2021-07-29

申请人： Vertex Pharmaceuticals Incorporated

发明人： Diane Boucher ,  Shawn M. Hillier ,  Wanjung Tsai ,  Brian Hare ,  William Markland ,  David A. Newsome ,  Marina S. Penney

IPC分类号： A61K31/704 ,  A61P35/00 ,  A61K9/127 ,  C07D401/14 ,  C07D403/14 ,  C07D471/04

摘要： Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.